CD8A and prostate neoplasm: Ezetimibe, a drug which inhibits the permeability of cholesterol to be taken up from the intestine, not only reduced serum cholesterol levels, but also inhibited mTORC2 signaling in CD8+ T-cells, increased infiltration of CD8+ T-cells into prostate tumors, and enhanced CD8+ memory lymphocytes with a central memory phenotype [53].